Exploring TMA. To explore a different substance…

Names:
TMA · AMM · EA-1319 · 3,4,5-Trimethoxyamphetamine
IUPAC name:
1-(3,4,5-Trimethoxyphenyl)propan-2-amine
ID: 157 · Formula: C12H19NO3 · Molecular weight: 225.284
InChI: InChI=1S/C12H19NO3/c1-8(13)5-9-6-10(14-2)12(16-4)11(7-9)15-3/h6-8H,5,13H2,1-4H3

Tsujikawa, K; Kanamori, T; Kuwayama, K; Miyaguchi, H; Iwata, YT; Inoue, H. Analytical profiles for 3,4,5-, 2,4,5-, and 2,4,6-trimethoxyamphetamine. Microgram J., 1 Jan 2006, 4 (1–4), 12–23. 162 kB.

Moya, PR; Berg, KA; Gutiérrez-Hernandez, MA; Sáez-Briones, P; Reyes-Parada, M; Cassels, BK; Clarke, WP. Functional selectivity of hallucinogenic phenethylamine and phenylisopropylamine derivatives at human 5-hydroxytryptamine (5-HT)2A and 5-HT2C receptors. J. Pharmacol. Exp. Ther., 1 Jun 2007, 321 (3), 1054–1061. 188 kB. http://dx.doi.org/10.1124/jpet.106.117507

Lemaire, D; Jacob, P; Shulgin, AT. Ring substituted beta-methoxyphenethylamines: a new class of psychotomimetic agents active in man. J. Pharm. Pharmacol., 1 Jan 1985, 37 (8), 575–7. 1.8 MB. http://dx.doi.org/10.1111/j.2042-7158.1985.tb03072.x

Shulgin, AT; Sargent, T; Naranjo, C. Structure-activity relationships of one-ring psychotomimetics. Nature, 1 Jan 1969, 221, 537–541. 537 kB. http://dx.doi.org/10.1038/221537a0

Shulgin, AT. Possible implication of myristicin as a psychotropic substance. Nature, 1 Jan 1966, 210, 380–384. 707 kB. http://dx.doi.org/10.1038/210380a0

Shulgin, AT; Bunnell, S; Sargent, T. The psychotomimetic properties of 3,4,5-trimethoxyamphetamine. Nature, 1 Jan 1961, 189, 1011–1012. 306 kB. http://dx.doi.org/10.1038/1891011a0 Rhodium.

Shulgin, AT. The six trimethoxyphenylisopropylamines (trimethoxyamphetamines). J. Med. Chem., 1 Jan 1966, 9 (3), 445–456. 362 kB. http://dx.doi.org/10.1021/jm00321a058

Ho, B; McIsaac, WM; An, R; Tansey, LW; Walker, KE; Englert, LF; Noel, MB. Analogs of α-methylphenethylamine (amphetamine). I. Synthesis and pharmacological activity of some methoxy and/or methyl analogs. J. Med. Chem., 1 Jan 1970, 13 (1), 26–30. 601 kB. http://dx.doi.org/10.1021/jm00295a007

Nichols, DE; Barfknecht, CF; Rusterholz, DB; Benington, F; Morin, RD. Asymmetric synthesis of psychotomimetic phenylisopropylamines. J. Med. Chem., 1 Jan 1973, 16 (5), 480–483. 515 kB. http://dx.doi.org/10.1021/jm00263a013

Peretz, DI; Smythies, JR; Gibson, WC. A new hallucinogen: 3,4,5-Trimethoxyphenyl-β-aminopropane. With notes on the stroboscopic phenomenon. Br. J. Psychiatry, 1 Jan 1955, 101 (423), 317–329. 1.6 MB. http://dx.doi.org/10.1192/bjp.101.423.317

Takahashi, M; Nagashima, M; Suzuki, J; Seto, T; Yasuda, I; Yoshida, T. Analysis of phenethylamines and tryptamines in designer drugs using gas chromatography-mass spectrometry. J. Health Sci., 2008, 54 (1), 89–96. 1.9 MB. http://dx.doi.org/10.1248/jhs.54.89

Sreenivasan, V. Problems in Identification of Methylenedioxy and Methoxy Amphetamines. J. Crim. Law Criminol., 1 Jan 1972, 63 (2), 304. 996 kB.

Weil, AT. The use of nutmeg as a psychotropic agent. Bull. Narc., United Nations Office on Drugs and Crime, 1 Jan 1966.

Fenderson5555. The trimethoxylated amphetamines (TMA-x). 9 Dec 2012. 7.7 MB.

Shulgin, AT. Chemistry and structure-activity relationships of the psychotomimetics. In Psychotomimetic Drugs; Efron, DH, Ed., Raven Press, New York, 1970; pp 21–41. 8.6 MB.

Anderson, GM; Braun, G; Braun, U; Nichols, DE; Shulgin, AT. Absolute configuration and psychotomimetic activity. In QuaSAR: Quantitative Structure Activity Relationships of Analgesics, Narcotic Antagonists, and Hallucinogens. NIDA Research Monograph 22; Barnett, G; Trsic, M; Willette, RE, Eds., U.S. Department of Health and Human Services, National Institute of Health, U.S. Government Printing Office, Washington, DC, 1978; pp 8–15. 457 kB.

Shulgin, AT; Sargent, T; Naranjo, C. The chemistry and psychopharmacology of nutmeg and of several related phenylisopropylamines. In Ethnopharmacologic Search for Psychoactive Drugs; Efron, DH; Holmstedt, B; Kline, NS, Eds., U.S. Department of Health and Human Services, National Institute of Health, U.S. Government Printing Office, Washington, DC, 28 Jan 1967; pp 202–215. 951 kB.

Guy, M; Freeman, S; Alder, JF; Brandt, SD. The Henry reaction: spectroscopic studies of nitrile and hydroxylamine by-products formed during synthesis of psychoactive phenylalkylamines. Cent. Eur. J. Chem., 1 Dec 2008, 6 (4), 526–534. 982 kB. http://dx.doi.org/10.2478/s11532-008-0054-z

Ray, TS. Psychedelics and the human receptorome. PLOS ONE, 2 Feb 2010, 5 (2), e9019. 791 kB. http://dx.doi.org/10.1371/journal.pone.0009019

Aldous, FAB; Barrass, BC; Brewster, K; Buxton, DA; Green, DM; Pinder, RM; Rich, P; Skeels, PM; Tutt, KJ. Structure-activity relationships in psychotomimetic phenylalkylamines. J. Med. Chem., 1 Oct 1974, 17 (10), 1100–1111. 1.2 MB. http://dx.doi.org/10.1021/jm00256a016

Glennon, RA; Liebowitz, SM; Anderson, GM. Serotonin receptor affinities of psychoactive phenalkylamine analogues. J. Med. Chem., 1 Mar 1980, 23 (3), 294–299. 844 kB. http://dx.doi.org/10.1021/jm00177a017

Domelsmith, LN; Eaton, TA; Houk, KN; Anderson, GM; Glennon, RA; Shulgin, AT; Castagnoli, N; Kollman, PA. Photoelectron spectra of psychotropic drugs. 6. Relationships between physical properties and pharmacological actions of amphetamine analogues. J. Med. Chem., 1 Jan 1981, 24 (12), 1414–1421. 963 kB. http://dx.doi.org/10.1021/jm00144a009

Pirisi, MA; Nieddu, M; Burrai, L; Carta, A; Briguglio, I; Baralla, E; Demontis, MP; Varoni, MV; Boatto, G. An LC-MS-MS method for quantitative analysis of six trimethoxyamphetamine designer drugs in rat plasma, and its application to a pharmacokinetic study. Forensic Toxicol., 1 Jul 2013, 31 (2), 197–203. 305 kB. http://dx.doi.org/10.1007/s11419-012-0177-y

Nelson, DL; Lucaites, VL; Wainscott, DB; Glennon, RA. Comparisons of hallucinogenic phenylisopropylamine binding affinities at cloned human 5-HT2A, 5-HT2B and 5-HT2C receptors. N-S. Arch. Pharmacol., 1 Jan 1999, 359 (1), 1–6. 66 kB. http://dx.doi.org/10.1007/PL00005315

Shulgin, AT. Psychotomimetic amphetamines: Methoxy 3,4-dialkoxyamphetamines. Experientia, 1 Jan 1964, 20 (7), 366–367. 240 kB. http://dx.doi.org/10.1007/BF02147960

Antun, F; Smythies, JR; Benington, F; Morin, RD; Barfknecht, CF; Nichols, DE. Native fluorescence and hallucinogenic potency of some amphetamines. Experientia, 15 Jan 1971, 27 (1), 62–63. 248 kB. http://dx.doi.org/10.1007/BF02137743

Shulgin, AT. Psychotomimetic drugs: structure-activity relationships. In Handbook of Psychopharmacology: Stimulants; Iversen, LL; Iversen, SD; Snyder, SH, Eds., Plenum Press, New York, 1978; Vol. 11, pp 243–333. 2.6 MB. http://dx.doi.org/10.1007/978-1-4757-0510-2_6 Rhodium.

Trachsel, D. Fluorine in psychedelic phenethylamines. Drug Test. Analysis, 1 Jul 2012, 4 (7-8), 577-590. 1.0 MB. http://dx.doi.org/10.1002/dta.413

Zaitsu, K; Katagi, M; Kamata, H; Kamata, T; Shima, N; Miki, A; Iwamura, T; Tsuchihashi, H. Discrimination and identification of the six aromatic positional isomers of trimethoxyamphetamine (TMA) by gas chromatography-mass spectrometry (GC-MS). J. Mass Spectrom., 1 Apr 2008, 43 (4), 528–534. 147 kB. http://dx.doi.org/10.1002/jms.1347

Bailey, K; Legault, D. 13C NMR spectra and structure of mono-, di- and trimethoxyphenylethylamines and amphetamines. Org. Magn. Resonance, 1 Jun 1983, 21 (6), 391–396. 680 kB. http://dx.doi.org/10.1002/omr.1270210611

Glennon, RA; Rosecrans, JA; Young, R. Behavioral properties of psychoactive phenylisopropylamines in rats. Eur. J. Pharmacol., 17 Dec 1981, 76 (4), 353–360. 964 kB. http://dx.doi.org/10.1016/0014-2999(81)90106-0

Makriyannis, A; Bowerman, D; Sze, PY; Fournier, D; De Jong., AP. Structure activity correlations in the inhibition of brain synaptosomal 3H-norepinephrine uptake by phenethylamine analogs. The role of α-alkyl side chain and methoxyl ring substitutions. Eur. J. Pharmacol., 9 Jul 1982, 81 (2), 337–340. 313 kB. http://dx.doi.org/10.1016/0014-2999(82)90454-X

Glennon, RA; Titeler, M; McKenney, JD. Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. Life Sci., 17 Dec 1984, 35 (25), 2505–2511. 332 kB. http://dx.doi.org/10.1016/0024-3205(84)90436-3

Glennon, RA; Raghupathi, R; Bartyzel, P; Teitler, M; Leonhardt, S. Binding of phenylalkylamine derivatives at 5-HT1C and 5-HT2 serotonin receptors: evidence for a lack of selectivity. J. Med. Chem., 1 Feb 1992, 35 (4), 734–740. 1.1 MB. http://dx.doi.org/10.1021/jm00082a014

Altun, A; Golcuk, K; Kumru, M; Jalbout, AF. Electron-conformation study for the structure-hallucinogenic activity relationships of phenylalkylamines. Bioorg. Med. Chem., 1 Dec 2003, 11 (24), 3861–3868. 577 kB. http://dx.doi.org/10.1016/S0968-0896(03)00437-1

Glennon, RA; Dukat, M; Grella, B; Hong, S; Costantino, L; Teitler, M; Smith, C; Egan, C; Davis, K; Mattson, MV. Binding of β-carbolines and related agents at serotonin (5-HT2 and 5-HT1A), dopamine (D2) and benzodiazepine receptors. Drug Alcohol Depend., 1 Aug 2000, 60 (2), 121–132. 276 kB. http://dx.doi.org/10.1016/S0376-8716(99)00148-9

Hardman, HF; Haavik, CO; Seevers, MH. Relationship of the structure of mescaline and seven analogs to toxicity and behavior in five species of laboratory animals. Toxicol. Appl. Pharmacol., 1 Jun 1973, 25 (2), 299–309. 751 kB. http://dx.doi.org/10.1016/S0041-008X(73)80016-X

Scorza, M; Carrau, C; Silveira, R; Zapata-Torres, G; Cassels, BK; Reyes-Parada, M. Monoamine oxidase inhibitory properties of some methoxylated and alkylthio amphetamine derivatives. Biochem. Pharmacol., 15 Dec 1997, 54 (12), 1361–1369. 697 kB. http://dx.doi.org/10.1016/S0006-2952(97)00405-X

Halberstadt, AL; Geyer, MA. Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens. Neuropharmacology, 1 Sep 2011, 61 (3), 364–381. 817 kB. http://dx.doi.org/10.1016/j.neuropharm.2011.01.017

Nakanishi, K; Miki, A; Zaitsu, K; Kamata, H; Shima, N; Kamata, T; Katagi, M; Tatsuno, M; Tsuchihashi, H; Suzuki, K. Cross-reactivities of various phenethylamine-type designer drugs to immunoassays for amphetamines, with special attention to the evaluation of the one-step urine drug test Instant-View™, and the Emit® assays for use in drug enforcement. Forensic Sci. Int., 10 Apr 2012, 217 (1–3), 174–181. 397 kB. http://dx.doi.org/10.1016/j.forsciint.2011.11.003

Thakur, M; Thakur, A; Khadikar, PV. QSAR studies on psychotomimetic phenylalkylamines. Bioorg. Med. Chem., 15 Feb 2004, 12 (4), 825–831. 323 kB. http://dx.doi.org/10.1016/j.bmc.2003.10.027

N-Me-TMA · METHYL-TMA
N-HO-TMA
1542
AEM
M
APM
ABM
AAM
AHM
ASM
ANM
α-D
α-HMe-M
α-CMe-M
α-MM-M
α-MV-M
AOM
α-TFMM
α-Carboxy-mescaline
β-HO-TMA
TA
2-I-TMA
3-Cl-4,5-DMA
α-Me-3-DESMETHYL
3,4,5-DOB
3,4,5-DOET
4,3,5-DOB · 4-Br-3,5-DMA
3C-BZ
3C-E
3C-FBZ
3C-P
3,5-DMA
3C-IP
3C-B
3C-A
3C-S
3C-H
3C-AL
3C-CPM
3C-FEM
3C-DFE
3C-TFM
3C-FP
3C-IB
3C-MAL
2335
4-Me-3,5-DOM
4,3,5-DOET
α-Me-DESMETHYL
2321
2322
4,3,5-DOPR
3,4-DMA
5-Me-3,4-DOM
327
MEDA
MMDA
MPDA · MTDA
MCPA · TMT
265
Elemicin
cis-Isoelemicin
Isoelemicin
Mescaline succinimide
Mescaline malimide
Mescaline citrimide
Mescaline maleimide
Mescaline isocitrimide lactone
Peyonine
Peyoglunal
Jimscaline
homo-Mescaline
α,N-Butenyl-M
N,N-Butenyl-M
M-βk
TMAT
504
1310
1311
1312
1528
1529
1530
1531
3,4,5-Trimethoxybenzylamine
BOD
E
ME
TMA-2
TMA-3
TMA-4
TMA-5
TMA-6
METHYL-MESCALINE
2C-O-2
N,N-Me-3-DESMETHYL
N,N-Me-DME · Macromerine
4C-HO
homo-Mescaline
β-HO-N-iPr-GEA
N-Me-β,3,4-TMPEA
DMMAOH
DEE
β-HO-N,N-Me-2,5-DMPEA
β-HO-β,N-Me-2,5-DMPEA
β-HO-N-Me-2,5-DMA
β,2-HO-N-Me-5-EA
β-HO-2,5-DEPEA
β-HO-N,N-Me-3,5-DMPEA
N-HO-DOM
DESMETHYL-MM
β-HO-DOM
1016
N-MeO-3,4-DMA
N-Me-TMA · METHYL-TMA
N-HO-TMA
1542
AEM
M
APM
ABM
AAM
AHM
ASM
ANM
α-D
α-HMe-M
α-CMe-M
α-MM-M
α-MV-M
AOM
α-TFMM
α-Carboxy-mescaline
β-HO-TMA
TA
2-I-TMA
3-Cl-4,5-DMA
α-Me-3-DESMETHYL
3,4,5-DOB
3,4,5-DOET
4,3,5-DOB · 4-Br-3,5-DMA
3C-BZ
3C-E
3C-FBZ
3C-P
3,5-DMA
3C-IP
3C-B
3C-A
3C-S
3C-H
3C-AL
3C-CPM
3C-FEM
3C-DFE
3C-TFM
3C-FP
3C-IB
3C-MAL
2335
4-Me-3,5-DOM
4,3,5-DOET
α-Me-DESMETHYL
2321
2322
4,3,5-DOPR
3,4-DMA
5-Me-3,4-DOM
327
MEDA
MMDA
MPDA · MTDA
MCPA · TMT
265
Elemicin
cis-Isoelemicin
Isoelemicin
Mescaline succinimide
Mescaline malimide
Mescaline citrimide
Mescaline maleimide
Mescaline isocitrimide lactone
Peyonine
Peyoglunal
Jimscaline
homo-Mescaline
α,N-Butenyl-M
N,N-Butenyl-M
M-βk
TMAT
504
1310
1311
1312
1528
1529
1530
1531
3,4,5-Trimethoxybenzylamine
BOD
E
ME
TMA-2
TMA-3
TMA-4
TMA-5
TMA-6
METHYL-MESCALINE
2C-O-2
N,N-Me-3-DESMETHYL
N,N-Me-DME · Macromerine
4C-HO
homo-Mescaline
β-HO-N-iPr-GEA
N-Me-β,3,4-TMPEA
DMMAOH
DEE
β-HO-N,N-Me-2,5-DMPEA
β-HO-β,N-Me-2,5-DMPEA
β-HO-N-Me-2,5-DMA
β,2-HO-N-Me-5-EA
β-HO-2,5-DEPEA
β-HO-N,N-Me-3,5-DMPEA
N-HO-DOM
DESMETHYL-MM
β-HO-DOM
1016
N-MeO-3,4-DMA
18 August 2017 · Creative Commons BY-NC-SA ·